ANI Pharmaceuticals (ANIP) Q2 FY26 earnings call

ANI Pharmaceuticals delivered a strong second quarter, marked by record revenues and EBITDA, driven by robust performance in its rare disease and generics segments. The company is actively transforming into a leading rare disease player, notably through a significant sales force expansion for Cortrophin Gel in the gout market, which is showing promising early indicators. While full-year Cortrophin guidance was modestly adjusted for first-half performance, the company remains confident in its strategic priorities and expects continued growth and operational leverage in 2027.